Skip to main content

External members of the advisory council

External Members

There shall be a minimum of seven (7) Members external to Cornell (3-year term, renewable).

Preferably, external members will be alumni with expertise in life sciences and/or entrepreneurial success and/or experience as a professional investor in life science ventures in the venture capital and/or industrial context. In recognition of his critical role in the founding of the Center, Kevin McGovern's term will be renewed automatically. Mr. McGovern's seat on the Council is not transferable to friends or family members.

Mr. McGovern and other informed individuals on the Council will provide the Senior Vice Provost of Research with nominations of appropriate candidates for these Council positions.

Kevin McGovern, JD, Chairman and CEO, McGovern Capital LLC

Kevin McGovern is the Chairman and CEO of McGovern Capital, LLC, which originates, structures and implements capital formation, joint ventures and business alliances. Mr. McGovern is also the principal of McGovern & Associates, a corporate law firm based in Greenwich, Connecticut. He is the Chairman of Greenwich Alliances, Ltd., which specializes in the formulation and negotiation of strategic alliances and serves on the Board of Directors of The Sports Authority.

He is a founder/key shareholder in over twenty companies, six of which are the worldwide leaders in their respective industry's product categories such as SoBe (nutriceutical beverages); NeoStrata (AHA skin care); KX Industries (water and air filters); Op40 (internet middleware); VLIW Technologies (microprocessor design) and Trakus (digital sports information). He is the Chairman of Angstrom Partners which is the first exclusive merchant bank in the nanotech industry (see www.kevinmcgovern.com for additional information). Angstrom has just formally announced a joint publication with Forbes to produce a monthly newsletter on Nanotechnology for worldwide distribution. He is a Fellow at the Foresight Institute, a leading think-tank organization relating to emerging technologies in Nanoscience.

Mr. McGovern is a member of Cornell's Board of Trustees and he is a Founder, Cornell Club NYC; he is also a member of the Cornell Advisory Council, Entrepreneurship@Cornell, the Arts and Sciences School Council, and the Athletic Council. Mr. McGovern has a law degree from St. John's University School of Law and studied at the London School of Economics and Political Science; he is a member of the Connecticut, New York and Pennsylvania Bars and is a member of the Executive Committee of the Connecticut Bar Association Section on Corporations.

Andrew Firlik, MD, General Partner, Foundation Medical Partners

Dr. Firlik's career spans neurosurgery, entrepreneurship, and venture capital. He joined Foundation Medical Partners to concentrate on medical device, healthcare information technology, and connected health investments. Prior to Foundation, he was a venture partner at Sprout Group and Managing Director of its healthcare technology spinout, New Leaf Venture Partners. Previously, he was a principal at Canaan Partners. Dr. Firlik has led numerous venture capital investments and has served as a founder, founding investor, or director of many early stage companies that have grown to become successful market leaders.

Dr. Firlik was a founder and an inventor of the core technology platform of Northstar Neuroscience, a medical device company that pioneered a novel approach to neuromodulation for the treatment of stroke and other disorders. Northstar went public in an IPO in 2006 (NASDAQ: NSTR) and was subsequently acquired by St. Jude Medical. He recently served as the Chairman of Intelect Medical (acquired by Boston Scientific, NYSE: BSX), a neuromodulation company, and recently served as Chairman of NovaVision, a medical therapeutics firm focusing on neuroplasticity for visual disorders. His current or recent board seats include BridgePoint Medical (acquired by Boston Scientific Corporation, NYSE: BSX), Clear Catheter Solutions, Explorys, Functional Neuromodulation, i1 Biometrics, NeuroVista, SetPoint Medical, Spine Wave, Vertos Medical, and Visiogen (acquired by Abbott, NYSE: ABT). Dr. Firlik is a member of the Innovation Advisory Board at Cleveland Clinic. He recently served as a member of the Administrative Board of the Cornell University Council and Chairman of its Technology Transfer Committee and also the Cornell University Biomedical Engineering Advisory Council and the Life Sciences Advisory Board.

Dr. Firlik spent 12 years in the healthcare profession during his medical training and practice as a neurological surgeon. He has published more than 50 articles in the medical literature, written chapters for several medical textbooks, and is the co-editor of a book about cerebrovascular surgery. His scientific work has been presented at many international conferences. He has been an inventor of numerous issued patents.

He studied biology at Cornell University and Oxford University, received his Masters of Business Administration from the University of Pittsburgh, and his M.D. from Cornell University Medical College. As a board certified neurosurgeon, Dr. Firlik most recently served as Clinical Assistant Professor of Neurosurgery at the New York University School of Medicine.

David R. Fischell, PhD, CEO, Angel Medical Systems, Inc

David Fischell is a serial entrepreneur who has founded nine biomedical device companies in the last fifteen years, including Angel Medical Systems. He is also a Director of eight biomedical technology companies (including five of those he founded) and was the primary designer of the BX Velocity™ and Cypher™ coronary stents for Cordis, a Johnson & Johnson Company.

David is chairman of the Cornell University Biomedical Engineering Advisory Board, and a Fellow of the American Institute for Medical and Biological Engineering. Other companies founded by David include Neuralieve, Inc. (2002) a developer of transcranial magnetic stimulation systems for migraine headaches; and NeuroPace, Inc. (1997) a developer of implantable brain pacemakers to treat epilepsy.

After earning his Ph.D. in Applied Physics from Cornell University, David joined Bell Laboratories in 1979 where, for 11 years, he performed and directed a wide range of research and development projects. He left Bell Labs in 1991 to work full time on medical devices. He currently holds 85 issued U.S. patents, and has published numerous papers in the fields of telecommunications, cardiology, radiobiology, and radiation dosimetry.

Gene Resnick, MD, Executive Vice President and Chief Medical Officer, Aptiv Solutions Inc

Dr. Resnick is the Chief Medical Officer and oversees the Aptiv Solutions medical affairs group including safety/pharmacovigilance, medical writing group and translational sciences group. Previously, Dr. Resnick had served as Averion’s Chief Medical Officer since 2006. He is a board-certified oncologist with over 30 years of experience in cancer drug-development. He founded an oncology-focused CRO, Millennnix Inc, which was acquired by Averion’s predecessor company in 2005, and which acquired and reverse merged operations to form Averion International in 2007.

Previously, Dr. Resnick held the positions of Vice President, Clinical Research – Oncology, at the Schering-Plough Research Institute (1992-1997) where he was responsible for all domestic and international Phase I – III clinical research projects in oncology, including development of 12 small molecules, biologics, cytokines and gene therapy products. He participated in multiple IND/NDA filings, and led the multi-disciplinary oncology product licensing and collaboration development.

Prior to that, he was Vice President, Medical Affairs at In Vivo, Inc.(1989-1992), where he was instrumental in expanding post-marketing program activities to include pivotal Phase I-III clinical trials in several therapeutic areas. He acted as liaison to pharmaceutical/biotech sponsors’ clinical, scientific, and medical-marketing staff, and provided expert, FDA-compliant medical monitor function. Dr. Resnick is Board-Certified in Medical Oncology and Internal Medicine, and is a member of ASCO, DIA, AACR and ACP. He received his BS (1970) from Cornell University, and his MD (1974) from Weill Cornell Medical College; he currently serves on the Cornell University Board of Trustees.

Philip Reilly, MD, JD, Venture Partner, 3rd Rock Ventures

Phil Reilly joined Third Rock Ventures in 2009, and supports the firm's founding and advancement of new ventures, with a particular focus on seeking to nurture and grow transformational companies dedicated to breakthrough treatments for genetic disorders. Phil is an accomplished entrepreneur, and has a long standing interest in genetic testing and in developing new therapies for genetic diseases. Phil has also held numerous teaching positions at Tufts University School of Medicine, Harvard Medical School, Cornell University and adjunct professor of both legal studies and biology at Brandeis University.

Phil holds an M.D. from Yale University, a J.D. from Columbia University and a BA from Cornell. He is a member of the Massachusetts Bar and board certified in internal medicine and clinical genetics. He is currently a trustee of Cornell University.

Phil has served twice (2000 & 2003) as President of the American Society of Law, Medicine, and Ethics. He also served on the Board of Directors of the American Society for Human Genetics and is a current Board Member of Edimer Pharmaceuticals.

William E. Rhodes, MS, former President, BD Biosciences Cell Analysis

William (Bill) Rhodes is the president of BD Biosciences Cell Analysis, a leading supplier of flow cytometry instruments and reagents for life sciences research and cell-based clinical diagnostics. Mr. Rhodes previously served as BD's vice president of Business Development and Strategic Investments at their corporate offices, where he had worldwide responsibility for business development activities. He also managed BD Ventures L.L.C., a corporate venture capital fund operated by BD. The fund focuses on investments in seed and early stage medical device, cell therapy and diagnostics companies.

Rhodes has more than 25 years of experience in the healthcare industry, and has held senior business development positions in J&J and Pfizer, before joining Becton Dickinson in late 1998. From 1983 until 1993 he was the president of The William-James Co., a biomedical business consulting firm specializing in M&A activities and technology due diligence in the biotechnology industry. 

He holds a Master of Science degree in International Business from Seton Hall University, and served on their faculty in the W. Paul Stillman School of Business as an adjunct professor, teaching graduate courses in the management of technological innovation and mergers and acquisitions. Rhodes also holds a Bachelor of Science degree from Cornell University, and is the author of 10 U.S. patents and numerous articles in the field of biomedical product development and investing.

MORE TO COME...